Bradmer sponsors physician panel to raise awareness of brain cancer treatments

TORONTO, Nov 05, 2008 /PRNewswire-FirstCall via COMTEX/ -- TSX: BMR

Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, announced today that it is participating in a GBM (glioblastoma multiforme) Awareness Day as a co-host with Voices Against Brain Cancer.

The event will take place on Wednesday, November 12, 2008, at the Four Seasons Hotel in New York City. The panel discussion will begin at 4:15pm ET. Dr. Alan M. Ezrin, President and Chief Executive Officer of Bradmer will present the Company's Neuradiab(TM) therapy, and an expert panel of physicians will discuss current trends and therapeutic advancements in the treatment of GBM, the most common and most advanced form of brain cancer.

    The expert panelists include:
    Steven Rosenfeld, M.D., Columbia University Medical Center (Moderator)
    Henry Friedman, M.D., Duke University Medical Center
    Keith Black, M.D., Cedars-Sinai Medical Center
    Pamela New, M.D., Methodist Neurological Institute
    Joycelyn Speight, M.D., Ph.D., University of California, San Francisco,
     Medical School
    David A. Reardon, M.D., Duke University Medical Center
    Michael R. Zalutsky, Ph.D., Duke University Medical Center
    David M. Bailey, Patient Advocate

The event will be broadcast live via a webcast presentation accessible from the Company's website at www.bradmerpharma.com. Please connect at least 15 minutes prior to the start time to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived for 30 days on Bradmer's website.

About Glioblastoma Multiforme

Glioblastoma multiforme (GBM) is the most common and most advanced form of brain cancer with approximately 30,000 new cases diagnosed each year in the world's seven largest healthcare markets. Unlike many other solid tumors, GBM tumors do not metastasize, but cause symptoms and often death through invasion of nearby tissues and impairment of brain function. The current standard of care, consisting of surgery, radiation and adjuvant chemotherapy (temozolomide), extended average overall patient survival from 53 to 64 weeks.

About the GLASS-ART Trial(TM) ( www.glassarttrial.com)

The Phase III GLASS-ART Trial derives its name from its description: GBM Locoregional Agent Survival Study - Antitenascin Radiolabeled antibody Therapy Trial. The study is designed to determine the survival benefit derived from, and safety of, adding Neuradiab to the current standard of care therapy for patients diagnosed with primary glioblastoma multiforme. The randomized trial will enroll up to 760 patients at leading treatment centers across the United States. Additional information on the trial can be found at www.glassarttrial.comor at www.clinicaltrials.gov and then by searching the term "Bradmer" or the study identifier NCT00615186.

About Neuradiab(TM)

Neuradiab is a monoclonal antibody, conjugated to radioactive iodine, used to treat glioblastoma multiforme (GBM), the most common and most advanced form of brain cancer. Neuradiab delivers tumor-killing radiation specifically to residual brain tumor cells after surgery, with minimal impact on normal brain tissue. During the course of development at Duke University, over US$60 million in research grants and related support has produced a series of Phase I and Phase II clinical trials on Neuradiab and other closely related technologies. Approximately 200 brain cancer patients, including over 160 with GBM, have been treated with the Neuradiab therapy regimen, and survival benefits have significantly exceeded historical controls in each completed trial. Neuradiab has been formerly referred to in literature as 131-I anti-tenascin monoclonal antibody 81c6.

GBM tumors typically have infiltrating edges that are very difficult to completely remove with surgery. The Neuradiab therapy is delivered directly into the surgical resection cavity in a separate procedure after the initial surgery. Neuradiab delivers a concentrated level of radiation specifically to the remaining cancer cells by targeting tenascin. Tenascin is a protein over-expressed in 99% of GBM cells but absent from normal brain cells.

About Bradmer Pharmaceuticals Inc. ( www.bradmerpharma.com)

Bradmer Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. Bradmer has initiated enrollment in a Phase III multi-center clinical trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.

Bradmer Pharmaceuticals Inc.'s common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

SOURCE Bradmer Pharmaceuticals Inc.